Publicaciones en colaboración con investigadores/as de Hospital de la Santa Creu i Sant Pau (85)

2023

  1. Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma

    Haematologica, Vol. 108, Núm. 1, pp. 110-121

  2. Correction: Role of allogeneic hematopoietic cell transplant for relapsed/refractory aggressive B-cell lymphomas in the CART era (Bone Marrow Transplantation, (2023), 58, 6, (673-679), 10.1038/s41409-023-01949-x)

    Bone Marrow Transplantation

  3. Early progression in follicular lymphoma in the absence of histological transformation or high-risk Follicular Lymphoma International Prognostic Index still has a favourable outcome

    British Journal of Haematology, Vol. 200, Núm. 3, pp. 306-314

  4. Extranodal natural killer/T-cell lymphoma nasal type in a western population: Molecular profiling identifies new therapeutic targets

    American Journal of Hematology

  5. Impact of SCHOLAR-1 Criteria on Chimeric Antigen Receptor T Cell Therapy Efficacy in Aggressive B Lymphoma: A Real-World GELTAMO/GETH Study

    Transplantation and Cellular Therapy, Vol. 29, Núm. 12, pp. 747.e1-747.e10

  6. One-year breakthrough SARS-CoV-2 infection and correlates of protection in fully vaccinated hematological patients

    Blood Cancer Journal, Vol. 13, Núm. 1

  7. Quantifying the available capacity and resource needs for provision of CAR-T therapies in the National Health Service in Spain: a survey-based study

    BMJ open, Vol. 13, Núm. 7, pp. e071371

  8. Remdesivir or Nirmatrelvir/Ritonavir Therapy for Omicron SARS-CoV-2 Infection in Hematological Patients and Cell Therapy Recipients

    Viruses, Vol. 15, Núm. 10

  9. Role of allogeneic hematopoietic cell transplant for relapsed/refractory aggressive B-cell lymphomas in the CART era

    Bone Marrow Transplantation, Vol. 58, Núm. 6, pp. 673-679

  10. SARS-CoV-2-reactive antibody waning, booster effect and breakthrough SARS-CoV-2 infection in hematopoietic stem cell transplant and cell therapy recipients at one year after vaccination

    Bone Marrow Transplantation, Vol. 58, Núm. 5, pp. 567-580

2022

  1. Allogeneic Hematopoietic Stem Cell Transplantation in Transformed Follicular Lymphoma (tFL): Results of a Retrospective Multicenter Study from GELTAMO/GETH-TC Spanish Groups

    Cancers, Vol. 14, Núm. 22

  2. Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma; Insights into Its Potential Role in the Era of New Immunotherapeutic and Targeted Therapies: The GETH/GELTAMO Experience

    Cancers, Vol. 14, Núm. 11

  3. Applicability of probabilistic graphical models for early detection of SARS-CoV-2 reactive antibodies after SARS-CoV-2 vaccination in hematological patients

    Annals of Hematology, Vol. 101, Núm. 9, pp. 2053-2067

  4. Autologous stem-cell transplantation as consolidation of first-line chemotherapy in patients with peripheral T-cell lymphoma: a multicenter GELTAMO/FIL study

    Haematologica, Vol. 107, Núm. 11, pp. 2675-2684

  5. Genetic and phenotypic characterisation of HIV-associated aggressive B-cell non-Hodgkin lymphomas, which do not occur specifically in this population: diagnostic and prognostic implications

    Histopathology, Vol. 81, Núm. 6, pp. 826-840

  6. Phase II Trial of Allogeneic Transplantation Plus Novel Drugs in Multiple Myeloma: Effect of Intensifying Reduced-Intensity Conditioning with Bortezomib and Adding Maintenance Treatment

    Transplantation and Cellular Therapy, Vol. 28, Núm. 5, pp. 258.e1-258.e8

  7. Revised International Prognostic Index and genetic alterations are associated with early failure to R-CHOP in patients with diffuse large B-cell lymphoma

    British Journal of Haematology, Vol. 196, Núm. 3, pp. 589-598

  8. SARS-CoV-2 vaccine response and rate of breakthrough infection in patients with hematological disorders

    Journal of hematology & oncology, Vol. 15, Núm. 1, pp. 54

  9. SARS-CoV-2-reactive antibody detection after SARS-CoV-2 vaccination in hematopoietic stem cell transplant recipients: Prospective survey from the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group

    American Journal of Hematology, Vol. 97, Núm. 1, pp. 30-42

2021

  1. Allogeneic Stem Cell Transplantation in Mature T Cell and Natural Killer/T Neoplasias: A Registry Study from Spanish GETH/GELTAMO Centers

    Transplantation and Cellular Therapy, Vol. 27, Núm. 6, pp. 493.e1-493.e8